Toxicology – Acetaminophen (Paracetamol): Repeated

Supratherapeutic Ingestion

Core Concept

Repeated supratherapeutic ingestion (RSTI) refers to excessive acetaminophen taken repeatedly over a period of time rather than as one clearly timed acute overdose.

It commonly occurs unintentionally when a person:

• Takes excessive doses for persistent pain or fever
• Uses several acetaminophen-containing products simultaneously
• Misunderstands product concentration or dosing
• Continues treatment longer or more frequently than intended

The major complication is hepatotoxicity from excessive formation of N-acetyl-p-benzoquinone imine (NAPQI).

The specific antidote is N-acetylcysteine (NAC).

RSTI vs Acute Single Ingestion

This distinction is essential.

Acute single ingestion

A large amount is taken at one reasonably well-defined time.

When appropriate, risk can be assessed using an appropriately timed acetaminophen concentration and the Rumack–Matthew nomogram.

Repeated supratherapeutic ingestion

Excessive acetaminophen is taken repeatedly over many hours or days.

In RSTI:

The Rumack–Matthew nomogram must NOT be used.

Instead, management is based on:

• Exposure history
• Serum acetaminophen concentration
• AST and ALT
• INR
• Clinical evidence of hepatic injury
• Risk factors and clinical course

Mechanism of Toxicity

Most therapeutic acetaminophen undergoes:

• Glucuronidation
• Sulfation

A smaller fraction undergoes CYP-mediated metabolism, particularly through CYP2E1, generating:

NAPQI

Normally:

NAPQI + glutathione → nontoxic conjugates

With excessive exposure:

↑ NAPQI + ↓ glutathione → mitochondrial injury → hepatocyte death

The centrilobular region of the liver is particularly vulnerable.

Why Repeated Ingestion Can Be Dangerous

With repeated excessive dosing, the patient may continuously generate NAPQI while hepatic glutathione reserves become progressively depleted.

Unlike a single overdose, there may be:

• No clear starting time
• No single peak acetaminophen concentration
• Ongoing absorption
• Ongoing toxic metabolite formation

Consequently, a relatively modest serum acetaminophen concentration can coexist with significant hepatic injury.

Do Not Rely on a Single “Toxic Dose”

The historical source uses fixed daily thresholds.

Modern assessment is more nuanced.

Risk depends on:

• Total dose
• Dose per unit body weight
• Duration of excessive dosing
• Age
• Nutritional status
• Fasting
• Intercurrent illness
• Hepatic function
• Alcohol exposure
• Timing of presentation

Dose history helps identify patients requiring evaluation, but it does not replace laboratory testing.

Common Causes of RSTI

Typical scenarios include:

• Severe dental pain
• Musculoskeletal pain
• Headache
• Persistent fever
• Viral illness
• Postoperative pain
• Caregiver dosing errors
• Multiple combination cold/flu products
• Simultaneous prescription and OTC acetaminophen products

Patients may genuinely be unaware that several products contain the same active ingredient.

Combination Products

Always check the complete ingredient list.

Acetaminophen may be combined with:

• Opioids
• Antihistamines
• Decongestants
• Caffeine
• Cough suppressants

Clinical findings may therefore reflect both acetaminophen and a coingestant.

Risk Factors

Potential vulnerability may be increased by circumstances associated with reduced glutathione reserves or altered metabolism, including:

• Prolonged fasting
• Malnutrition
• Significant chronic alcohol use
• Severe intercurrent illness
• Low body weight
• Other causes of poor nutritional intake

However, risk factors should not replace objective evaluation.

Alcohol – Important Nuance

The relationship between alcohol and acetaminophen toxicity is complex.

Chronic heavy alcohol use may be associated with:

• CYP2E1 induction
• Malnutrition
• Reduced glutathione reserves

Acute ethanol exposure, however, can transiently compete for CYP2E1.

Therefore:

Alcohol use alone does not determine whether toxicity will occur.

Acetaminophen concentration, liver tests, exposure pattern, and clinical findings remain more important.

Enzyme-Inducing Medications

Older teaching suggested that medications such as carbamazepine or isoniazid automatically produce a major increase in acetaminophen toxicity.

The clinical relationship is less straightforward.

Medication history remains relevant, but treatment decisions should not be based solely on presumed CYP induction.

Clinical Presentation

RSTI can be more difficult to recognize than a single acute overdose because patients often present after hepatic injury has already begun.

Possible early symptoms include:

• Nausea
• Vomiting
• Malaise
• Poor appetite
• Abdominal discomfort
• Right upper quadrant pain

Some patients have few symptoms despite substantial biochemical injury.

Hepatic Injury

Possible findings include:

• Rising AST
• Rising ALT
• Increasing INR
• Right upper quadrant tenderness
• Jaundice

Severe injury can progress to acute liver failure.

Acute Liver Failure

Severe acetaminophen hepatotoxicity may cause:

• Coagulopathy
• Hypoglycemia
• Lactic acidosis
• Hepatic encephalopathy
• Hyperammonemia
• Cerebral edema
• Acute kidney injury
• Hemodynamic instability
• Multiorgan failure

These patients require intensive monitoring and early specialist involvement.

Renal Injury

Acute kidney injury can accompany acetaminophen toxicity and occasionally occurs without proportionate hepatic injury.

Monitor:

• Creatinine
• Electrolytes
• Urine output

Severe renal failure may require renal replacement therapy for standard clinical indications.

Children

Repeated acetaminophen dosing errors can occur when:

• Different liquid concentrations are confused
• Adult formulations are used accidentally
• Multiple caregivers independently administer doses
• Fever persists and doses are given too frequently
• Several combination products are used

Young children may present with nonspecific findings such as:

• Lethargy
• Poor feeding
• Vomiting
• Dehydration

A careful medication history is essential.

Safeguarding Considerations

When the exposure history is inconsistent with the child’s developmental abilities or caregiver explanation, clinicians should consider:

• Medication error
• Unsafe medication storage
• Inadequate supervision
• Nonaccidental administration

This requires careful clinical and safeguarding assessment rather than assuming abuse solely from the child’s age.

Essential Laboratory Evaluation

When clinically significant RSTI is suspected, important tests include:

• Serum acetaminophen concentration
• AST
• ALT
• INR
• Creatinine
• Electrolytes
• Glucose

Additional testing depends on severity.

Serum Acetaminophen Concentration

A serum acetaminophen concentration remains useful in RSTI, but it is interpreted differently from an acute single ingestion.

A detectable concentration may indicate continuing exposure and ongoing risk.

However:

Do not plot it on the Rumack–Matthew nomogram.

A Low Level Does Not Mean Low Risk

In RSTI, substantial hepatic injury can occur when the serum acetaminophen concentration is relatively low.

Why?

Because the patient may have been taking acetaminophen repeatedly for days, and much of the earlier drug has already been metabolized.

Therefore:

Serum concentration must be interpreted together with AST/ALT and the clinical history.

Undetectable Acetaminophen

An undetectable concentration also does not automatically exclude acetaminophen-induced liver injury.

By the time severe hepatotoxicity becomes apparent:

• The last dose may have been many hours earlier.
• Parent acetaminophen may have been cleared.
• Hepatic injury may already be established.

This is particularly important in delayed presentations.

AST and ALT

Aminotransferases are central to assessment.

Significant acetaminophen hepatotoxicity can produce very large elevations.

Serial measurements are more useful than a single isolated result because the trajectory helps establish whether injury is:

• Developing
• Peaking
• Improving

INR

INR is an important marker of hepatic synthetic function in significant acetaminophen-associated liver injury.

A progressively rising INR is concerning.

However, INR should be interpreted with:

• AST/ALT
• Clinical status
• Glucose
• Lactate
• Renal function
• Encephalopathy

No single laboratory measurement defines overall prognosis.

Additional Tests in Severe Toxicity

Depending on the clinical situation, consider:

• Blood gas
• Lactate
• Bilirubin
• Phosphate
• CBC
• Ammonia in patients with encephalopathy
• Additional studies for alternative causes of acute liver failure

Rumack–Matthew Nomogram – Do Not Use

This is one of the highest-yield distinctions.

The nomogram assumes:

• A single ingestion
• A reasonably known ingestion time
• Predictable absorption kinetics

RSTI violates these assumptions.

Therefore:

Repeated ingestion + serum level ≠ nomogram plotting.

N-Acetylcysteine (NAC)

NAC remains the specific antidote.

It:

• Replenishes cysteine for glutathione synthesis
• Enhances detoxification of NAPQI
• Provides antioxidant effects
• Supports mitochondrial function
• May improve hepatic microcirculation in established liver injury

NAC should not be viewed as useful only before hepatotoxicity occurs.

When NAC Is Considered

NAC is appropriate when RSTI is associated with evidence suggesting clinically important acetaminophen exposure or hepatic injury.

Important findings include:

• A clinically meaningful detectable acetaminophen concentration
• Elevated AST or ALT in a compatible exposure
• Evidence of evolving acetaminophen-associated liver injury
• Uncertain exposure with concerning laboratory abnormalities

Current poison-center or medical-toxicology protocols should guide borderline cases.

Do Not Delay NAC in a Sick Patient

If a patient has:

• A convincing history of excessive acetaminophen exposure
• Significant aminotransferase elevation
• Coagulopathy
• Acute liver failure

NAC should not be delayed while waiting for every confirmatory test.

Its safety profile is favorable, and benefit can persist even after hepatic injury has developed.

NAC After Hepatic Injury Has Begun

NAC can improve outcomes even after the window for preventing initial NAPQI injury has passed.

Late benefits are thought to involve:

• Antioxidant activity
• Improved mitochondrial function
• Improved microcirculation
• Support of hepatic recovery

Therefore:

Late presentation is not a reason to withhold NAC.

Duration of NAC – Important Modern Correction

The historical source recommends treatment for a predetermined minimum period.

Modern management increasingly uses clinical and biochemical stopping criteria rather than an arbitrary duration alone.

NAC generally continues while there is evidence of ongoing toxicity, such as:

• Clinically relevant detectable acetaminophen
• Rising or substantially abnormal AST/ALT
• Worsening INR attributable to hepatic injury
• Deteriorating clinical status

Stopping NAC

Treatment may be stopped when appropriate clinical criteria are satisfied, typically including:

• Acetaminophen no longer clinically significant
• Aminotransferases improving or appropriately normal
• Hepatic synthetic function improving
• Patient clinically stable

Severe liver failure may require prolonged NAC despite disappearance of acetaminophen from blood.

Previous NAC Reaction

The older statement that previous anaphylaxis absolutely contraindicates NAC is too restrictive.

IV NAC can cause non-IgE-mediated anaphylactoid reactions, but these are often manageable.

When NAC is strongly indicated, a previous reaction generally warrants:

• Careful monitoring
• Appropriate management of hypersensitivity
• Specialist guidance

rather than automatic withholding of a potentially lifesaving antidote.

Activated Charcoal

Activated charcoal has a much smaller role in RSTI than in a recent single acute ingestion.

It may occasionally be appropriate if a substantial recent dose was taken and significant drug is still expected within the gastrointestinal tract.

However, most patients with RSTI present long after earlier doses have been absorbed.

Therefore:

Routine charcoal is not useful simply because repeated excessive dosing occurred.

Ipecac and Gastric Lavage

Neither has a routine role.

Do not induce vomiting.

Routine gastric lavage is not appropriate for RSTI.

Antiemetics

Vomiting should be managed appropriately, especially when it interferes with:

• Hydration
• Electrolyte correction
• Oral medications
• Antidotal treatment

Modern antiemetic selection should be individualized rather than following the older multidrug regimens automatically.

Coagulopathy

In acute liver failure, INR is both a marker of hepatic synthetic dysfunction and part of prognostic assessment.

Routine administration of plasma solely to normalize an abnormal INR is generally avoided in a patient without clinically important bleeding.

Unnecessary plasma can:

• Cause volume overload
• Cause transfusion reactions
• Obscure the natural INR trend

Blood products are used for appropriate bleeding or procedural indications.

Vitamin K

Vitamin K does not reverse acetaminophen hepatotoxicity.

It may be considered if concomitant vitamin K deficiency is suspected, but severe hepatic synthetic failure will not normalize simply because vitamin K is administered.

Cimetidine

Cimetidine was historically investigated as a way to reduce CYP-mediated NAPQI formation.

It has no established routine role in modern acetaminophen poisoning.

NAC remains the specific antidote.

Acute Liver Failure and Transplant Referral

Patients with severe acetaminophen-induced liver failure should be discussed early with a liver transplant center.

Do not wait until irreversible multiorgan failure develops.

Important prognostic features include:

• Encephalopathy
• INR trajectory
• Arterial pH
• Lactate
• Creatinine
• Hypoglycemia
• Hemodynamic instability
• Overall clinical trajectory

Established systems such as the King’s College criteria may assist assessment, but no single criterion should replace specialist evaluation.

Pregnancy

The historical FDA pregnancy letter categories are obsolete.

Pregnancy does not change the fundamental indication for NAC.

Maternal hepatic failure poses substantial fetal risk, so:

Treat the pregnant patient promptly when NAC is indicated.

NAC crosses the placenta.

Neonate After Maternal Toxicity

Routine administration of a fixed NAC course to every newborn after maternal acetaminophen poisoning is not a universal modern recommendation.

Neonatal management depends on:

• Maternal exposure
• Timing of poisoning
• Maternal NAC treatment
• Timing of delivery
• Neonatal acetaminophen concentration when relevant
• Neonatal hepatic status

Specialist neonatal/toxicology evaluation is appropriate.

Differential Diagnosis

Other causes of marked hepatic injury include:

• Ischemic hepatitis
• Viral hepatitis
• Autoimmune hepatitis
• Alcohol-associated hepatitis
• Amanita mushroom poisoning
• Valproate toxicity
• Other drug-induced liver injury
• Herbal or plant hepatotoxins

Acetaminophen exposure should nevertheless be considered in otherwise unexplained acute liver failure because the history may initially be incomplete.

Monitoring During Treatment

Depending on severity, follow:

• AST
• ALT
• INR
• Acetaminophen concentration when relevant
• Creatinine
• Electrolytes
• Glucose
• Mental status

In severe cases also monitor:

• Lactate
• Acid–base status
• Phosphate
• Hemodynamics
• Urine output
• Ammonia when clinically relevant

The direction of change is often more useful than one isolated result.

Expected Course

Patients identified and treated before severe liver failure generally have an excellent prognosis.

Even patients with significant hepatotoxicity can recover because the liver has substantial regenerative capacity.

Poor prognostic features include progressive:

• Encephalopathy
• Coagulopathy
• Lactic acidosis
• Renal failure
• Hypoglycemia
• Multiorgan dysfunction

Some patients ultimately require liver transplantation.

Discharge Principles

Medical discharge is appropriate only after clinicians establish that:

• Acetaminophen toxicity is no longer progressing
• Hepatic function is stable or improving
• Renal function is acceptable
• NAC has been appropriately discontinued
• The source of repeated excessive dosing has been addressed
• The patient or caregiver understands safe medication use

Intentional ingestion additionally requires appropriate safety assessment.

Prevention

A major cause of RSTI is accidental duplication.

Patients and caregivers should be taught to:

• Check the active ingredient on every product.
• Recognize that “acetaminophen” and “paracetamol” are the same medication.
• Avoid taking several acetaminophen-containing products simultaneously.
• Use age-appropriate pediatric formulations.
• Measure liquid medications accurately.
• Keep a dosing record when several caregivers are treating a child.
• Follow current product-specific dosing instructions.

Important Modernization of the Older Source

• The preferred term is repeated supratherapeutic ingestion (RSTI) rather than simply “chronic overdose.”
• RSTI does not have the predictable pharmacokinetics of a single acute ingestion.
• Never use the Rumack–Matthew nomogram for RSTI.
• Assessment relies primarily on exposure history, serum acetaminophen, AST/ALT, INR, renal function, and clinical findings.
• A relatively low acetaminophen concentration can coexist with severe hepatic injury.
• An undetectable concentration does not exclude late acetaminophen hepatotoxicity.
• Fixed historical dose thresholds are useful for screening but should not be treated as absolute toxicity boundaries.
• Malnutrition and prolonged fasting can increase vulnerability.
• The relationship between chronic alcohol exposure, CYP induction, and acetaminophen toxicity is more nuanced than older descriptions suggest.
• NAC remains beneficial even after hepatic injury develops.
• Modern NAC treatment uses clinical and laboratory stopping criteria, not simply a fixed minimum duration.
• A previous NAC reaction is not necessarily an absolute contraindication.
• Activated charcoal has only a limited role unless a substantial dose was taken recently.
• Routine plasma administration solely to normalize INR is generally inappropriate without bleeding or another specific indication.
• Cimetidine is not recommended.
• Severe acute liver failure warrants early liver-transplant-center consultation.
• Pregnancy is not a reason to withhold NAC.
• Routine fixed-course neonatal NAC after every maternal overdose is not universally indicated.
• Historical FDA pregnancy categories are obsolete.

Key Points

• RSTI = repeated excessive acetaminophen exposure over time rather than one clearly timed overdose.
• Do not use the Rumack–Matthew nomogram.
• Toxicity results from NAPQI formation + inadequate glutathione detoxification + mitochondrial hepatocyte injury.
• Check acetaminophen concentration + AST/ALT + INR + renal function.
• A low or undetectable acetaminophen concentration does not exclude established hepatotoxicity.
• NAC is the specific antidote and remains useful even after liver injury begins.
• Continue NAC until appropriate clinical and biochemical stopping criteria are met.
• Persistent vomiting, malnutrition, fasting, and unrecognized duplicate acetaminophen products are important clinical clues.
• Progressive encephalopathy, coagulopathy, acidosis, renal failure, or multiorgan dysfunction requires intensive management and early transplant-center involvement.
• Prevent recurrence by identifying all acetaminophen/paracetamol-containing products the patient has been using.